Document:

Exhibit 10.2

 

NAVIDEA BIOPHARMACEUTICALS, INC.

5600 Blazer Parkway, Suite 200Dublin,
Ohio 43017-7550 

 

 

THIS STOCK OPTION AGREEMENT (the “Agreement”),
made by and between Navidea Biopharmaceuticals, Inc. (the “Company”), and Ricardo J.Gonzalez (the “Optionee”),
is effective as of October 13, 2014 (the “Grant Date”).

 

WHEREAS, as an inducement for the Optionee’s
joining the Company as its President and Chief Executive Officer, and as additional consideration for his entry into the Employment
Agreement dated October 13, 2014 (the “Employment Agreement”), the Company wishes to afford the Optionee the
opportunity to purchase a number of shares of its common stock, $0.001 par value (“Shares”) pursuant to the
terms and conditions set forth in this Agreement;

 

NOW, THEREFORE, in consideration of the
mutual covenants herein contained and other good and valuable consideration, receipt of which is hereby acknowledged, the parties
hereto do hereby agree as follows:

 

ARTICLE
I

DEFINITIONS

 

As used in this Agreement the following
capitalized terms shall have the meanings defined below:

 

“Board” or “Board
of Directors” means the Board of Directors of the Company

 

“Change in Control” will
be deemed to have occurred if and when (i) a person, partnership, corporation, trust or other entity (“Person”) acquires
or combines with the Company, or 50 percent or more of its assets or earning power, in one or more transactions, and after such
acquisition or combination, less than a majority of the outstanding voting shares of the Person surviving such transaction (or
the ultimate parent of the surviving Person) is owned by the owners of the voting shares of the Company outstanding immediately
prior to such acquisition or combination, unless the Change in Control transaction or transactions have been approved in advance
by members of the Board representing at least two-thirds of the Board members; or (ii) during any period of two consecutive years
during the term of this Plan, individuals who at the beginning of such period are members of the Board (“Original Board
Members”) cease for any reason to constitute at least a majority of the Board, unless the election of each Board member
who was not an Original Board Member has been approved in advance by Board members representing at least two-thirds of the Board
members then in office who were Original Board Members. This definition shall be interpreted in accordance with the guidance under
Section 409A of the Internal Revenue Code that describes a change in control, change in effective control, and change in ownership
of a substantial portion of the assets of a corporation.

 

“Committee” means the
Compensation, Nominating and Governance Committee of the Board of Directors, or such other committee as the Board shall appoint
from time to time with responsibility for executive compensation and administration of equity incentive awards.

 

    	 

    	 

    

“Disabled” means a condition
that (i) causes the Optionee to be unable to engage in any substantial gainful activity by reason of any medically determinable
physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not
less than 12 months, (ii) causes the Optionee, by reason of any medically determinable physical or mental impairment that can be
expected to result in death or can be expected to last for a continuous period of not less than 12 months, to receive income replacement
benefits for a period of not less than three months under an accident and health plan covering employees of the Company or its
affiliates or (iii) causes the Optionee to be eligible to receive Social Security disability payments. The Committee, in its sole
discretion, shall determine the date of any Disability.

 

“Fair Market Value” means,
on any given date and as may be specified in this Agreement, (a) the closing sales price per share (or, if otherwise specified
by the Committee, a price that is based on the opening, actual, high, low, or average sales prices per Share) of the Company’s
common stock as reported on the NYSE MKT or such other established securities market on which the Shares are traded, or, if there
were no reported sales of Shares on such date, then, unless otherwise required under the Code, the business day immediately preceding
such date; or (b) if (a) does not apply, the price that the Committee in good faith determines through any reasonable valuation
method that a Share might change hands between a willing buyer and a willing seller, neither being under compulsion to buy or to
sell and both having reasonable knowledge of the relevant facts. Notwithstanding the above, for purposes of broker-facilitated
cashless exercises of Awards involving, “Fair Market Value” shall mean the real-time selling price of such Shares as
reported by the broker facilitating such exercises.

 

“Option” shall have the
meaning defined in Section 2.1.

 

“Option Price” shall
have the meaning defined in Section 2.2.

 

“Retire” or “Retirement”
means termination of Optionee’s employment by reason of his retirement at or after his or her having satisfied the requirements
for retirement under the applicable Company qualified retirement plan, or in such other termination of employment determined to
be a retirement by the Committee.

 

ARTICLE
II

GRANT OF OPTIONS

 

Section 2.1.   Grant of Option.

 

For good and valuable
consideration, on and as of the date hereof, the Company irrevocably grants to the Optionee an Option to purchase any part or all
of an aggregate number of 1,000,000 Shares, subject to the adjustment as set forth in Section 1.3 hereof (the “Option”).

 

Section 2.2.   Exercise Price.

 

Subject to Section
1.3 hereof, the per Share exercise price of the Shares covered by the Option shall be $1.26 (the “Exercise Price”).

 

Section 2.3.   Adjustments to
Option

 

    	2

    	 

    

(a)               
Appropriate adjustments in the aggregate number of Shares issuable pursuant to the Option and the Exercise Price shall be
made to give effect to any increase or decrease in the number of issued Shares resulting from a subdivision or consolidation of
Shares, whether through recapitalization, stock split, reverse stock split, spin-off, spin-out or other distribution of assets
to shareholders, stock distributions or combinations of Shares, payment of stock dividends, other increase or decrease in the number
of such Shares outstanding effected without receipt of consideration by the Company, or any other occurrence for which the Committee
determines an adjustment is appropriate.

 

(b)              
 In the event of any merger, consolidation or reorganization of the Company with any other corporation or corporations,
or an acquisition by the Company of the stock or assets of any other corporation or corporations, there shall be substituted on
an equitable basis, as determined by the Committee in its sole discretion, for Shares then subject to the Option, the number and
kind of Shares of stock, other securities, cash or other property to which Optionee is entitled pursuant to such transaction.

 

(c)               
Without limiting the generality of the foregoing provisions of this paragraph, any such adjustment shall be deemed to have
prevented any dilution or enlargement of Optionee’s rights, if Optionee receives in any such adjustment, rights that are
substantially similar (after taking into account the fact that the Optionee has not paid the applicable Exercise Price) to the
rights the Optionee would have received had he exercised his outstanding Option and become a shareholder of the Company immediately
prior to the event giving rise to such adjustment. Adjustments under this paragraph shall be made by the Committee, whose decision
as to the amount and timing of any such adjustment shall be conclusive and binding.

 

ARTICLE
III

VESTING AND EXERCISE OF OPTION

 

Section 3.1.   Vesting and Commencement
of Exercisability.

 

The Option shall vest
and become exercisable in three tranches, provided that the Optionee has been an employee of the Company continuously from the
date of this Agreement through the date when such portion of the Option vests. The first tranche of 300,000 Shares will vest and
become exercisable on the first anniversary of the Grant Date. The second tranche of 300,000 Shares will vest and become exercisable
on or after the second anniversary of the Grant Date, provided that the Option will not be exercisable with respect to such Shares
unless and until the average closing price per Share of the Company’s common stock for the ten trading days prior to exercise
equals or exceeds $2.50 per share. The third tranche of 400,000 shares will vest and become exercisable on or after the third anniversary
of the Grant Date, provided that the Option will not be exercisable with respect to such Shares unless and until the average closing
price per Share of the Company’s common stock for the ten trading days prior to exercise equals or exceeds $3.50 per share.

 

 

Section 3.2.   Expiration of
Option.

 

The unvested and unexercisable portion of
the Option shall automatically expire immediately upon:

 

    	3

    	 

    

(a)               
the tenth anniversary of the Grant Date;

 

(b)              
the date of the Optionee’s termination of employment, if the Optionee’s employment is terminated by the Company
“for cause” as defined in Section 4.A. of the Employment Agreement; or

 

(c)               
the date of the Optionee’s termination of employment as a result of Optionee’s voluntary resignation.

 

In the event that Optionee dies, Retires,
or becomes Disabled prior to termination of this Option without having fully exercised the Option, Optionee or his successor shall
have the right to exercise the option during its term within a period of one year after the date of such termination due to death,
Disability or Retirement, to the extent that the Option option was exercisable at the date of termination due to death, Disability
or retirement, or during such other period and subject to such terms, including accelerated vesting, as may be determined by the
Committee.

 

Section 3.3.   Acceleration
of Vesting of Option.

 

(a)               
Any portion of the Option that has not previously become vested pursuant to Section 2.1 and has not expired or been terminated
pursuant to Section 2.2 shall immediately become vested and exercisable upon the termination by the Company of Optionee’s
employment “without cause,” as defined in Section 4.D. of the Employment Agreement, and in such event, any unexercised
portion of the Option shall remain exercisable for a period of ninety (90) days following such termination of employment.

 

(b)              
Any portion of the Option that has not previously become vested pursuant to Section 2.1 and has not expired or been terminated
pursuant to Section 2.2 shall immediately become vested and exercisable upon the occurrence of a Change in Control of the Company.
Further, the Committee, as constituted before such Change in Control, is authorized, and has sole discretion: (i) provide for the
cancellation of any unvested portion of the Option for an amount of cash equal to the difference between the exercise price and
the then Fair Market Value of the Shares covered thereby had such Options been currently exercisable; (ii) make such adjustment
to the Options then outstanding as the Committee deems appropriate to reflect such Change in Control; or (iii) cause any unexercised
portion of the Option then outstanding to be assumed, by the acquiring or surviving corporation, after such Change in Control.

 

Section 3.4.   Exercise.

 

This Option may be
exercised by the delivery of this Agreement with the notice of exercise attached hereto properly completed and signed by Optionee
to the Treasurer of the Company, together with the aggregate Exercise Price for the number of Shares as to which the Option is
being exercised, after the Option has become exercisable and before it has ceased to be exercisable. The Exercise Price must be
paid (i) in cash, (ii) by authorizing a third party with which Optionee has a brokerage or similar account to sell the Shares (or
a sufficient portion of such Shares) acquired upon the exercise of the Option and remit to the Company a portion of the sale proceeds
sufficient to pay the entire Exercise Price to the Company, (iii) by delivering Shares that have an aggregate Fair Market Value
on the date of exercise equal to the Exercise Price; (iv) by authorizing the Company to withhold from the total number of Shares
as to which the Option is being exercised the number of Shares having a Fair Market Value on the date of exercise equal to the
aggregate Exercise Price for the total number of Shares as to which the Option is being exercised, or (v) by any combination of
(i), (ii), (iii), and (iv). In the case of an election pursuant to (i) above, cash shall mean cash or check made payable to Navidea
Biopharmaceuticals, Inc. In the case of payment pursuant to (ii) or (iii) above, Optionee’s authorization must be made
on or prior to the date of exercise and shall be irrevocable.

 

    	4

    	 

    

Section 3.5.   Rights as a Stockholder.

 

The Optionee
shall not be, and shall not have any of the rights or privileges of, stockholders of the Company in respect of any Shares purchasable
in connection with the Option or any portion thereof unless and until a book entry representing such Shares has been made on the
books and records of the Company.

 

Section 3.6.   Forfeiture Conditions.

 

Notwithstanding any
provision herein to the contrary, in the event of termination Optionee’s employment “for cause” as defined in
Section 4.A. of the Employment Agreement, the breach of any non-competition or confidentiality restrictions applicable to Optionee,
or Optionee’s participation in an activity that is deemed by the Committee to be detrimental to the Company, (i) Optionee’s
right to exercise any unexercised portion of the Option shall immediately terminate and all rights thereunder shall cease, (ii)
Optionee’s right to receive an issuance of Shares upon settlement of the Option shall immediately terminate, and, (iii) if
the Option has been exercised, in whole or in part, then either (A) the Shares issued upon exercise of the Option shall be forfeited
and returned to the Company and Optionee shall be repaid the lesser of (x) the then-current Fair Market Value per Share or (y)
the Exercise Price paid for such Option Shares, or (B) Optionee will be required to pay to the Company in cash an amount equal
to the gain realized by Optionee from the exercise of such Option (measured by the difference between the Fair Market Value of
the Option Shares on the date of exercise and the Exercise Price paid by Optionee).

 

ARTICLE
IV

MISCELLANEOUS

 

Section 4.1.   Administration.

 

The Committee shall
have the power to interpret this Agreement. All actions taken and all interpretations and determinations made by the Committee
shall be final and binding upon the Optionee and his beneficiaries or successors, the Company and all other interested persons.
No member of the Committee shall be personally liable for any action, determination or interpretation made in good faith with respect
to the the Option. In its absolute discretion, the Board may at any time, and from time to time, exercise any and all rights and
duties of the Committee under this Agreement.

 

    	5

    	 

    

Section 4.2.   Option Not Transferable.

 

This Option may not
be sold, pledged nor otherwise transferred other than by will or the laws of descent and distribution; and it may only be exercised
during by Optionee during his lifetime. Notwithstanding the foregoing, Optionee may transfer this Option either (a) to members
of his immediate family (as defined in Rule 16a-1 under the Securities Exchange Act of 1934, as amended), to one or more trusts
for the benefit of such family members, or to partnerships or other entities in which such family members are the only partners
or owners, provided that Optionee does not receive any consideration for the transfer, or (b) with the prior written approval of
the Committee. Any Option held by a transferee remains subject to the same terms and conditions that applied immediately prior
to transfer based on the transferor’s continuing relationship with the Company. This Agreement is neither a negotiable instrument
nor a security (as such term is defined in Article 8 of the Uniform Commercial Code).

 

Section 4.3.   Notices.

 

Any notice to be given under the terms of
this Agreement to the Company shall be addressed to the Company in care of its Secretary, and any notice to be given to the Optionee
shall be addressed to the Optionee at the most recent address of the Optionee set forth in the personnel records of the Company.
By a notice given pursuant to this Section 4.3, either party may hereafter designate a different address for notices to
be given to that party. Any notice which is required to be given to the Optionee, shall, if the Optionee is then deceased, be given
to the Optionee’s personal representative if such representative has previously informed the Company of the representative’s
status and address by written notice under this Section 4.3. Any notice shall have been deemed duly given when enclosed
in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch post
office regularly maintained by the United States Postal Service.

 

Section 4.4.   Titles; Interpretation.

 

Titles are provided herein for convenience
only and are not to serve as a basis for interpretation or construction of this Agreement. Defined terms used in this Agreement
shall apply equally to both the singular and plural forms thereof. Whenever the context may require, any pronoun shall include
the corresponding masculine, feminine and neuter forms. The words “include”, “includes” and “including”
shall be deemed to be followed by the phrase “without limitation”. The term “hereunder” shall mean this
entire Agreement as a whole unless reference to a specific section or provision of this Agreement is made. Any reference to a Section,
subsection and provision is to this Agreement unless otherwise specified.

 

Section 4.5.   No Right to Employment
or Additional Options or Stock Awards.

 

Nothing in this Agreement shall confer upon
the Optionee any right to continue in employment, or shall interfere with or restrict in any way the rights of the Company and
its affiliates, which are hereby expressly reserved, to terminate the employment of the Optionee at any time for any reason whatsoever,
with or without cause, subject to the applicable provisions, if any, of the Employment Agreement (if any such agreement is in effect
at the time of such termination). Neither the Optionee nor any other Person shall have any claim to be granted any additional Options
or any other stock awards.

 

    	6

    	 

    

Section 4.6.   Nature of Grant.

 

In accepting the Option, the Optionee acknowledges
that, regardless of any action the Company or its affiliates takes with respect to any or all income tax, social insurance, payroll
tax, payment on account or other tax-related withholding (“Tax-Related Items”), the Optionee acknowledges that
the ultimate liability for all Tax-Related Items legally due by the Optionee is and remains the Optionee’s responsibility,
and the Optionee shall pay to, and indemnify and keep indemnified, the Company and its affiliates from and against Tax-Related
Items legally due by the Optionee that are attributable to the exercise of, or any benefit derived by the Optionee from, the Option
and that the Company and its affiliates (i) make no representations or undertakings regarding the treatment of any Tax-Related
Items in connection with any aspect of this Agreement, including the grant, vesting or exercise of this Option, the subsequent
sale of Shares acquired pursuant to such exercise or the receipt of any dividends with respect to such Shares; and (ii) do not
commit to structure the terms of the grant or any aspect of the Option to reduce or eliminate the Optionee’s liability for
Tax-Related Items. Optionee acknowledges that this Option is not an incentive stock option under Section 422 of the Internal Revenue
Code, and that Optionee will have taxable income upon the exercise of this Option. At that time, you must pay to Navidea an amount
equal to the required federal, state and local tax withholding less any withholding otherwise made from your salary or bonus.

 

Section 4.7.   Governing Law.

 

This Agreement shall be governed in all
respects by the laws of the State of Delaware, without regard to conflicts of law principles thereof.

 

Section 4.8.   Entire Agreement.

 

This Agreement sets
forth the entire agreement of the parties with respect to the subject matter hereof and it supersedes and discharges all prior
agreements (written or oral) and negotiations and all contemporaneous oral agreements concerning such subject matter. This Agreement
may not be amended or terminated except by a writing signed by the party against whom any such amendment or termination is sought.

 

IN WITNESS WHEREOF, this Agreement has been
executed and delivered by the parties hereto.

 

	 	NAVIDEA BIOPHARMACEUTICALS, INC.
	 	 
	 	/s/ Brent L. Larson                             
	 	Name: Brent L. Larson
	 	Title: Executive Vice President & 

          Chief Financial Officer

 

 

    	7

    	 

    

 

	 	Optionee
	 	 
	 	/s/ Ricardo J. Gonzalez
	 	Ricardo J. Gonzalez
	 	 

 

 

 

    	8

    	 

    

 

OPTION EXERCISE FORM

 

 

The undersigned hereby
exercises the right to purchase ____________________ shares of Common Stock of Navidea Biopharmaceuticals, Inc. pursuant to the
Option Agreement dated October __, 2014.

 

 

	 	 	Approved by (President, CEO or
	 	 	EVP/CFO):
	 	 	 
	 	 	 
	Optionee Signature	Date	 	Signature	Date

 

 

 

Sign and complete this Option Exercise
Form and deliver it to:

 

Navidea Biopharmaceuticals, Inc.

Attn: Chief Financial Officer

5600 Blazer Parkway

Suite 200

Dublin, Ohio 43017-7550

 

together with the option price in cash
(i) in cash, (ii) by authorizing a third party with which you have a brokerage or similar account to sell the Shares (or a sufficient
portion of such Shares) acquired upon the exercise of the Option and remit to Navidea a portion of the sale proceeds sufficient
to pay the entire Exercise Price to Navidea, (iii) by delivering Shares that have an aggregate Fair Market Value on the date of
exercise equal to the Exercise Price; (iv) by authorizing Navidea to withhold from the total number of Shares as to which the Option
is being exercised the number of Shares having a Fair Market Value on the date of exercise equal to the aggregate Exercise Price
for the total number of Shares as to which the Option is being exercised, or (v) by any combination of (i), (ii), (iii), and (iv).

 

    	9Amendment No. 2 to Credit Agreement

 Exhibit 10.1 

EXECUTION COPY 
 AMENDMENT NO. 2
TO THE 
 CREDIT AGREEMENT 

Dated as of October 9, 2014 

AMENDMENT NO. 2 TO THE CREDIT AGREEMENT (this “Amendment”) among YAHOO! INC., a Delaware corporation (the
“Borrower”), the banks, financial institutions and other institutional lenders that are parties to the Credit Agreement referred to below (collectively, the “Lenders”) and CITIBANK, N.A., as administrative agent
(the “Agent”) for the Lenders. 
 PRELIMINARY STATEMENTS: 

(1) The Borrower, the Lenders and the Agent have entered into a Credit Agreement dated as of October 19, 2012, as amended by Amendment
No. 1 dated as of October 10, 2013 (the “Credit Agreement”). Capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Credit Agreement. 

(2) The Borrower, the Lenders and the Agent have agreed to amend the Credit Agreement as hereinafter set forth. 

SECTION 1. Amendments to Credit Agreement. The Credit Agreement is, effective as of the date hereof and subject to the satisfaction of
the conditions precedent set forth in Section 3, hereby amended as follows: 
 (a) The definition of “Base
Rate” in Section 1.01 is hereby amended by replacing the phrase “British Bankers Association Interest Settlement Rate” with the phrase “ICE Benchmark Settlement Rate”. 

(b) The definition of “EBITDA” in Section 1.01 is hereby amended by deleting from clause (f) the
phrase “$100,000,000 for the four fiscal quarter period ended September 20, 2012 and not to exceed an additional $100,000,000 in any period of four consecutive fiscal quarters commencing after September 30, 2012” and substituting
therefor the phrase “an amount not to exceed $100,000,000 in any period of four consecutive fiscal quarters”. 

(c) The definition of “Eurodollar Rate” in Section 1.01 is hereby amended by deleting the following:

 or, if for any reason such rate is not available, the rate per annum at which deposits in U.S. dollars are offered
by the principal office of Citibank in London, England to prime banks in the London interbank market at 11:00 A.M. (London time) two Business Days before the first day of such Interest Period in an amount substantially equal to Citibank’s
Eurodollar Rate Advance comprising part of such Borrowing to be outstanding during such Interest Period and for a period equal to such Interest Period 

(d) The definition of “Termination Date” in Section 1.01 is amended by deleting the date “October
9, 2014” and substituting therefor the date “October 8, 2015”. 

 (e) The following definitions are added to Section 1.01 in appropriate
alphabetical order: 
 “Anti-Corruption Laws” means the United States Foreign Corrupt Practices Act of
1977, as amended, and the UK Bribery Act, as amended. 
 “Sanctions” means any applicable international
economic sanctions administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or
(b) the European Union. 
 “Sanctioned Country” means, at any time, a country which is subject to
comprehensive economic sanctions by the United States that broadly restrict trade and investment with that country (at the time of this Agreement, Cuba, Iran, North Korea, Sudan and Syria). 

“Sanctioned Person” means, at any time, (a) any Person listed in any Sanctions-related list of
designated Persons maintained and published by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, the European Union or Her Majesty’s Treasury of the United Kingdom, (b) any Person
operating, organized or resident in a Sanctioned Country or (c) any Person owned or controlled by any such Person or Persons. 

(f) Section 4.01 is amended by adding a new subsection (j) to the end thereof, to read as follows: 

(j) The Borrower has implemented and maintains in effect policies and procedures designed to ensure compliance by the
Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and the Borrower and its Subsidiaries, and, to the knowledge of a responsible officer of the Borrower,
their respective officers, employees, directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects. None of (a) the Borrower or any its Subsidiary or (b) to the knowledge of a
responsible officer of the Borrower, any of their respective directors, officers, employees or agents that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person. 

(g) Section 5.01(a) is amended by adding to the end thereof the following: 

; and maintain in effect and enforce policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries
and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions. 
 (h)
Section 5.02(e)(vii) is amended by adding to the end of clause (B) thereof the following: “or any successor or successors to the global treasury operations of the Borrower and its Subsidiaries”. 

(i) Section 5.02 is amended by adding a new subsection (f) to the end thereof, to read as follows: 

 (f) Use of Proceeds. No Borrowing or use of proceeds of any Borrowing
under this Agreement will directly, or to the knowledge of a responsible officer of the Borrower, indirectly (x) be made available to any Person for the purpose of financing or facilitating any activity in any Sanctioned Country, or any
activity with any Person currently subject to any Sanction, in each case, in violation of the applicable Sanctions, or (y) be used for any payments to any governmental official or employee, political party, official of a political party,
candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of Anti-Corruption Laws, in any material respect. 

SECTION 2. Waiver. By execution below, the Borrower, the Agent and the Required Lenders hereby waive (a) the requirement of
Section 2.20(a) of the Credit Agreement that notice of request to extend the Termination Date be delivered by the Borrower not later than 30 days prior to the Termination Date, (b) the requirement of Section 2.20(b) of the Credit
Agreement that the Notice Date be not later than 20 days prior to the Extension Date and (c) the requirement of Section 2.20(c) of the Credit Agreement that the Agent shall notify the Borrower of each Lender’s response to extension
request not later than 15 days prior to the Extension Date. 
 SECTION 3. Conditions of Effectiveness. This Amendment shall become
effective as of the date first above written (the “Effective Date”) when, and only when, (a) the Agent shall have received counterparts of this Amendment executed by the Borrower and the Required Lenders, (b) the Borrower
shall have paid to the Agent, for the benefit of the Lenders, all reasonable and documented fees then due and payable (including the reasonable and documented accrued fees and out-of-pocket expenses of counsel to the Agent) and (c) and the
Agent shall have additionally received all of the following documents, each such document (unless otherwise specified) dated the date of receipt thereof by the Agent (unless otherwise specified), in form and substance reasonably satisfactory to the
Agent: 
 (a) Certified copies of the resolutions of the board of directors (or persons performing similar functions) of the
Borrower approving transactions of the type contemplated by this Amendment. 
 (b) A certificate signed by a duly authorized
officer of the Borrower stating that: 
 (i) The representations and warranties contained in Section 4 are correct in
all material respects (except to the extent such representations and warranties are qualified by materiality in the text thereof, in which case such representations and warranties shall be true and correct) on and as of the Effective Date (except to
the extent such representations and warranties expressly refer to an earlier date, in which case such representations and warranties shall be made on and as of such earlier date); and 

(ii) No event has occurred and is continuing that constitutes a Default. 

SECTION 4. Representations and Warranties of the Borrower The Borrower represents and warrants as follows: 

(a) The Borrower is a corporation duly organized, validly existing and in good standing under the laws of the State of
Delaware. 
 (b) The execution and delivery by the Borrower of this Amendment and the performance by the Borrower of the
Credit Agreement (as amended hereby) and the consummation of the transactions contemplated hereby and thereby are within the Borrower’s corporate powers, have been duly authorized by all necessary corporate action, do not contravene
(i) the Borrower’s charter or by laws, (ii) law or (iii) any material contractual restriction binding on or affecting the Borrower. 
  

 (c) No authorization or approval or other action by, and no notice to or filing
with, any governmental authority or regulatory body is required for the due execution and delivery by the Borrower of this Amendment and performance by the Borrower of the Credit Agreement (as amended hereby), except to the extent that any such
authorization, approval, action, notice or filing has been completed or is immaterial. 
 (d) This Amendment has been duly
executed and delivered by the Borrower. This Amendment and the Credit Agreement (as amended hereby) are the legal, valid and binding obligations of the Borrower enforceable against the Borrower in accordance with their respective terms, subject to
(i) bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors and (ii) general principles of equity, regardless of whether applied in proceedings in
equity or at law. 
 (e) There is no pending or, to the knowledge of the Borrower, threatened action, suit, investigation,
litigation or proceeding, including, without limitation, any Environmental Action, affecting the Borrower or any of its Subsidiaries before any court, governmental agency or arbitrator that (i) would reasonably be expected to have a Material
Adverse Effect (other than as disclosed in the Borrower’s filings with the Securities and Exchange Commission, including on forms 10-K, 10-Q, 8-K, and DEF 14A filed prior to the Effective Date) or (ii) purports to affect the legality,
validity or enforceability of this Amendment, the Credit Agreement (as amended hereby) or the consummation of the transactions contemplated hereby and thereby. 

(f) The Consolidated balance sheet of the Borrower and its Subsidiaries as at December 31, 2013, and the related
Consolidated statements of income and cash flows of the Borrower and its Subsidiaries for the fiscal year then ended, accompanied by an opinion of PricewaterhouseCoopers LLP, independent public accountants, and the Consolidated balance sheet of the
Borrower and its Subsidiaries as at June 30, 2014, and the related Consolidated statements of income and cash flows of the Borrower and its Subsidiaries for the six months then ended, duly certified by the chief financial officer of the
Borrower, copies of which have been furnished or made available to each Lender, fairly present, in all material respects, subject, in the case of said balance sheet as at June 30, 2014, and said statements of income and cash flows for the six
months then ended, to year-end audit adjustments and the absence of footnotes, the Consolidated financial condition of the Borrower and its Subsidiaries as at such dates and the Consolidated results of the operations of the Borrower and its
Subsidiaries for the periods ended on such dates, all in accordance with generally accepted accounting principles consistently applied. Since December 31, 2013, there has been no Material Adverse Change (other than as disclosed in the
Borrower’s filings with the Securities and Exchange Commission, including on forms 10-K, 10-Q, 8-K, and DEF 14A filed prior to the Effective Date). 

(g) the representations and warranties contained in Section 4.01(g), (h), (i) and (j) of the Credit Agreement,
as amended hereby, are correct in all material respects (except to the extent such representations and warranties are qualified by materiality in the text thereof, in which case such representations and warranties shall be true and correct). 

 

 SECTION 5. Reference to and Effect on the Credit Agreement. (a) On and after the
effectiveness of this Amendment, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Credit Agreement, and each reference in each of the Notes to
“the Credit Agreement”, “thereunder”, “thereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement, as amended by this Amendment. 

(b) The Credit Agreement and each of the Notes as specifically amended by this Amendment, are and shall continue to be in full
force and effect and are hereby in all respects ratified and confirmed. 
 (c) The execution, delivery and effectiveness of
this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Agent under the Credit Agreement, nor constitute a waiver of any provision of the Credit Agreement. 

SECTION 6. Execution in Counterparts. This Amendment may be executed in any number of counterparts and by different parties hereto in
separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Amendment by
telecopier or other electronic means shall be effective as delivery of a manually executed counterpart of this Amendment. 
 SECTION 7.
Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws of the State of New York. 
 [The
remainder of this page is intentionally left blank] 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their
respective officers thereunto duly authorized, as of the date first above written. 
  

			
	YAHOO! INC.
		
	By	 	 /s/ Ken Goldman

	Name:	 	Ken Goldman
	Title:	 	CFO

 Agreed as of the date first above written: 

 

			
	CITIBANK, N.A., as Agent and a Lender
		
	By	 	 /s/ Susan M. Olsen

	Name:	 	Susan M. Olsen
	Title:	 	Vice President
	
	HSBC BANK USA, NATIONAL ASSOCIATION,
		
	By	 	 /s/ David Wagstaff

	Name:	 	David Wagstaff
	Title:	 	Managing Director
	
	BANK OF AMERICA, N.A.,
		
	By	 	 /s/ Prayes Majmudar

	Name:	 	Prayes Majmudar
	Title:	 	Director
	
	JPMORGAN CHASE BANK, N.A.,
		
	By	 	 /s/ Nicolas Gitron-Bear

	Name:	 	Nicolas Gitron-Bear
	Title:	 	Vice President
	
	THE ROYAL BANK OF SCOTLAND PLC,
		
	By	 	 /s/ Alex Daw

	Name:	 	Alex Daw
	Title:	 	Director
	
	GOLDMAN SACHS BANK USA, as a Lender
		
	By	 	 /s/ Rebecca Kratz

	Name:	 	Rebecca Kratz
	Title:	 	Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]